A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

This study has been terminated.
(Revisiting product options)
Sponsor:
Collaborator:
Advanced Clinical Research
Information provided by (Responsible Party):
Zarbee's Inc.
ClinicalTrials.gov Identifier:
NCT01588249
First received: April 26, 2012
Last updated: October 9, 2012
Last verified: October 2012

April 26, 2012
October 9, 2012
April 2012
June 2012   (final data collection date for primary outcome measure)
Change from baseline in cough frequency between the first night and the end of the second night. [ Time Frame: baseline and day 2 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01588249 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection
A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

Cough is a frequent symptom in children and infants and is one of the most common reasons parents visit a healthcare provider for their child. The US Food and Drug Administration has issued a warning that over-the-counter cough and cold medicines including antihistamines, decongestants, anti-tussives, and expectorants should not be administered to children younger than 2 years of age due not only to lack of proven efficacy, but also because of important safety concerns. A product that has been used in alternative medicine for cough is maple syrup. Although no studies have formally evaluated the use of maple syrup for nocturnal cough associated with URI, the demulcent effect of maple syrup may provide some relief from cough in children. A novel formulation of pasteurized maple cough syrup, when compared to placebo, should provide superior relief on nocturnal cough and the sleep difficulty associated with URI in children under 12 months and sleep difficulty of their parent/caregiver.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Cough
  • Upper Respiratory Infection
  • Nocturnal Cough
  • Dietary Supplement: Pasteurized maple syrup
  • Dietary Supplement: Placebo
  • Experimental: Novel formulation of pasteurized maple cough syrup
    Intervention: Dietary Supplement: Pasteurized maple syrup
  • Placebo Comparator: Placebo
    Intervention: Dietary Supplement: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
80
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria

  1. Otherwise healthy male or female infant who is between 0 and 12 months of age.
  2. Presents to clinic with a URI characterized by the presence of rhinorrhea and cough for 7 or fewer days' duration.
  3. Patient is an appropriate candidate, in the judgment of the investigator, to participate in the study.
  4. Parents/caregivers provide an answer of at least "somewhat" (3 points on a 7-point Likert scale) for a minimum of 2 of the 3 questions related to nocturnal cough frequency, effect on child's sleep, and effect on parental/caregiver sleep based on the previous night's symptoms (see Section 11.0).
  5. Parent/legal authorized representative provides written informed consent for child to participate in study.
  6. Parent/caregiver who is willing and able to comply with study requirements.

Exclusion Criteria

  1. Signs or symptoms of a more treatable disease (eg, asthma, pneumonia, laryngotrachebronchitis, sinusitis, allergic rhinitis).
  2. Diagnosis of influenza, bronchiolitis or respiratory syncytial virus (RSV).
  3. History of reactive airways disease, asthma, or chronic lung disease.
  4. Use of any medication to treat cough within 6 hours of bedtime on the evening prior to or on the day of enrollment. (Use of analgesic medications such as acetaminophen or ibuprofen is not exclusionary.)
  5. Presence of any significant disease including immunodeficiency, hepatic, renal, cardiovascular, or hematologic disease or any other health condition that, in the opinion of the investigator, would preclude participation in the study.
Both
up to 12 Months
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01588249
ZMCS-6441
Not Provided
Zarbee's Inc.
Zarbee's Inc.
Advanced Clinical Research
Not Provided
Zarbee's Inc.
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP